Titre :
|
Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. (2001)
|
Auteurs :
|
Joel BLOSTEIN ;
Patricia-A CLARK
|
Type de document :
|
Article
|
Dans :
|
Public health reports (vol. 116, n° 2, 2001)
|
Pagination :
|
165-168
|
Langues:
|
Anglais
|
Mots-clés :
|
Hépatite virale B
;
Virose
;
Infection
;
Dépistage
;
Adolescent
;
Homme
;
Prise de risque
;
Analyse coût efficacité
;
Economie santé
;
Vaccination
;
Age
;
Etats Unis
;
Amérique
;
Prévention santé
;
Appareil digestif [pathologie]
;
Foie [pathologie]
;
Amérique du Nord
|
Résumé :
|
[BDSP. Notice produite par INIST-CNRS qMvdcR0x. Diffusion soumise à autorisation]. Objective. The goals of this study were to estimate seroprevalence of prior hepatitis B infection among high-risk adolescents and to determine the cost-effectiveness of prevaccination immunity screening. Methods. The authors computed a "break-even" seroprevalence level calculated from current vaccine and administration costs. They then conducted a seroprevalence study of hepatitis B core antibody using sera previously submitted for syphilis serology from four-hundred adolescent and adult clients of sexually transmitted disease clinics. Finally, the authors compared age group-specific seroprevalence rates to the computed break-even seroprevalence. Results. Levels of prior hepatitis B infection for all age groups were lower than the break-even seroprevalence standard from which cost-effectiveness was calculated. Conclusions. From the findings of this study, the authors concluded that routine preimmunization screening for prior hepatitis B infection would not be cost-effective for this population.
|